Three development trends of China's biomedical industry and the arrival of the era of doctor industry innovation

With the continuous breakthrough of biomedical industry technology and the introduction of policies, the development of China's biomedical industry shows a trend of centralized and digital development, and doctors are becoming more and more important in industrial innovation I industrial trend: centralization, industrial restructuring (I) regional centralization and differentiation to develop core city industrial clusters The core cities are relatively complete in talent base, scientific research base, enterprise base, policy system and capital system, and the industry starts earlier At present, a relatively complete industrial cluster has been formed, such as Shanghai, Beijing, Suzhou, Guangzhou, etc The industrial ecosystem and coordination circle centered on the core city have been initially formed Due to the high cost of entrepreneurship and the change of urban functional orientation in large cities, some local biomedical industry clusters have completed the initial period of resource concentration, and began to appear industrial spillover The industrial clusters of core cities and surrounding cities, such as the Yangtze River Delta, the Bohai Sea Rim and the Pearl River Delta, have initially emerged Industrial upgrading of core cities accelerates source innovation Some leading industrial clusters in China have covered the whole process of early product discovery, clinical research and development, production, circulation and other industries through talent introduction, special policies, leading enterprises, etc., and regional industrial development also pays more attention to source innovation For example, Shanghai proposed to vigorously develop the source innovation of biomedical industry in 2015, and issued 32 innovation articles in 2018 to promote the innovation and development of regional industry source The differential development of biomedical industry in non core cities is the general trend Biopharmaceutical industry has a high demand for resource agglomeration and a strong dependence on policy The development of its industrial cluster is affected by regional industrial basis, enterprise basis, policy basis, capital environment, business environment and other aspects Based on the current situation of localization industry and the development experience of leading regions, it is very important for regions to formulate the industrial positioning and industrial development strategies suitable for regional development And a large number of biomedical industry development zones with distinctive industrial characteristics have emerged in China （2） The introduction of China 2030 marks the real arrival of the era of China's big health industry The industry has expanded from the raw materials, medical devices, circulation, medical services and other links of the traditional biomedical industry to cover the five subdivisions of "medicine, health, health, health and medicine" Small innovation and large-scale service With the introduction of major policies such as MAH pilot, deepening of medical reform, 36 items, consistency evaluation of generic drugs, etc., the demand for innovation in the biomedical industry is becoming higher and higher, and the control of the circulation link is becoming more and more strict How to quickly improve the innovation ability, and based on the scale effect, improve the R & D, production, circulation service ability and reduce the marginal cost will face new challenges Referring to the development path of foreign biomedical industry, we can see that multinational pharmaceutical enterprises occupy the market rapidly through innovation in the early stage, integrate industry innovation resources through capital in the middle and late stage, and deeply cultivate the company's clinical capacity, production capacity, channel development and control ability According to the characteristics of industry development and relevant national policies, in the next few years, the domestic biomedical industry will gradually appear in the fields of cro, CMO and CSO, and at present, the leading enterprises in the domestic biomedical industry, which are relatively advanced in development, are running fast through capital In addition, the biomedical industry cluster led by the government or the park is also exploring the source innovation of enterprises The park is equipped with corresponding service institutions (currently mainly cro and CMO started to appear rapidly in 2017), allowing scientists to focus on early research and development links, and accelerating the innovation process through a large-scale service platform Such as the construction of innovation service platform of BioBAY in Suzhou, such as technical service, supply chain service, etc With the breakthrough of artificial intelligence technology, data and intelligent technology are becoming more and more important in the development of biomedical industry R & D intelligence A large number of pharmaceutical companies around the world, such as Merck, novatis, Roche, Pfizer, Johnson & Johnson, have begun to explore the combination of artificial intelligence and new drug research and development, accelerate the process of new drug research and development through intelligent technology, and improve the efficiency of research and development At present, the main intelligent applications include new drug design, physical and chemical property prediction, pharmaceutical analysis, disease diagnosis target, drug combination and so on And in the process of drug research and development, data has been everywhere Industry digital collaboration The biomedical industry has a high degree of complexity and a large number of subdivisions The information isolated island between the links of various industries is more serious, and the efficiency of industrial coordination is cross How to build a global biomedical industry innovation resources collaborative system, break the information asymmetry through digital technology, and accelerate the circulation and transaction frequency of information and resources Third, the era of biomedical industry innovation with doctors as the main body is coming Doctors are an important part of biomedical industry innovation They are also the most familiar groups in the industry, who are familiar with the needs of patients, diagnosis and treatment products Draw lessons from the medical device R & D model of Israel with doctors as the source of innovation, take doctors as the starting point of innovation idea, and equip with corresponding financial support institutions, incubators, cro institutions to accelerate innovation R & D, and withdraw to realize income through capital, so as to form a regional industrial development culture focusing on early innovation Since 2016, a large number of doctors in China have started to come out of the hospital Through the establishment of doctor groups such as Zhang Qiang and song Donglei, the efficiency of medical resource circulation has been improved In recent years, doctors have participated in many cases of biomedical product innovation: Professor Huo Yong from the first hospital of Peking University participated in and led the research of H-type hypertension recognition and treatment, and the national first-class new drug enalapril folate tablets, detection kits, and amlodipine folate tablets have been on the market Professor Zhang Xu, director of Urology, General Hospital of the people's Liberation Army, Bayer Steyr medical robot technology (Tianjin) Co., Ltd., "prostate 3D ultrasound navigation and positioning system", Beijing Jishuitan Hospital has developed the first general orthopedic operation robot in China, Tianji Through the continuous transformation of doctors' innovative achievements, the research on innovative sources and achievements transformation mechanism of biomedical industry in China with doctors as the core may be formed How to integrate doctors' innovative resources through effective cooperation mechanism and related technologies, and set up corresponding service platforms to provide large-scale service capacity and industrialization capacity are the main problems to be faced.